Skip to content
OpenCapital
Get started

Tarsus Pharmaceuticals, Inc. TARS Operating Lease Liability Payments - 2028 (Lessee)

Operating Lease Liability Payments - 2028 (Lessee) at other companies

Warby Parker logo
Warby ParkerWRBY
——

Other financials

Income statement

See full
Revenue$162.1M+107%
Gross profit$152.7M+109%
Operating income-$6.1M+76.7%
Net income-$7.0M+72.3%
EPS (diluted)-$0.16+75.0%

Balance sheet

See full
Cash & equivalents$104.2M-41.6%
Total debt$88.7M+22.5%
Total equity$349.0M+1.9%
Total assets$581.1M+16.1%

Cash flow

See full
Operating cash flow-$24.7M-19.4%
CapEx$5.8M+886%
Free cash flow-$30.5M-43.4%

Valuation

See full
Market cap$2.85B+41.1%
Enterprise value$2.83B+47.8%
P/S5.3×-3.3×

Profitability

See full
Gross margin42.7%—
Operating margin-9.5%-4.2pp
Net margin-9%-4.0pp
FCF margin-28%-12.6pp

Returns & leverage

See full
Return on equity-14%-5.2pp
Debt / equity0.3×0.0×
Current ratio3.7×-1.8×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour.

The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tarsus Pharmaceuticals, Inc.'s operating lease liability payments - 2028 (lessee).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tarsus Pharmaceuticals, Inc.'s operating lease liability payments - 2028 (lessee)?
Tarsus Pharmaceuticals, Inc. (TARS) reported operating lease liability payments - 2028 (lessee) of $2.87M in Q1 2026.
What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s operating lease liability payments - 2028 (lessee)?
Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s operating lease liability payments - 2028 (lessee) has grown at a 156.6% compound annual growth rate (CAGR), from $25K to $2.78M.